Title: Breast Cancer Campaign Tissue Bank Site Visit Leeds 21409
1The Independent Cancer Patients Voice a warm
welcome to Leeds!
2Programme
- 11.15 Collection use of tissue and its value
to cell biology - Val Speirs, Debbie Holliday, Laura Smith, Aidan
Hindley - 13.00 Lunch
- with Dave Ardon, Chair NCRI Consumer Liaison
Group - 14.00 Bone related issues in breast cancer
treatment - Rob Coleman
- 15.00 Consultation on measures of emotional
distress - Lucy Ziegler
- 16.00 Tea ICPV discussion
- 16.30 Different methods of breast reconstruction
- Raj Achuthan
- 17.30 Lab tour
- Steven Pollock Michele Cummings
3Collection and use of tissue and its value to
cell biology
- Valerie Speirs
- Deborah Holliday
- Laura Smith
4Breast cancerOne disease or many?
5(No Transcript)
6If it looks different, it is different
7310
8Frequency of chromosomal aberrations in breast
cancer
Grade I
Grade II
Roylance et al., Cancer Res 1999
9Breast cancer is heterogeneous One size does not
fit all!
10How can we model breast cancer in the lab?
- Cell lines
- Animal models
- Human clinical material
11Cell lines
- Cons
- origin
- genetic drift
- reproducibility
- Pros
- ease of use
- homogeneous
- easily replaced
12Burdall et al., Breast Cancer Res, 2003
13Case study MCF-7
- Morphology
- similar in all cases
- Growth rate
- variable
- Karyotype (CGH/SKY)
- variable
- ER/PR content
- variable
- Separate MCF-7 strains from different
laboratories
14Animal models
- Breast cancer is a complex disease which is not
easily modelled in animals - Concerns over the validity of animal models
- breast tumours taken from animal experiments do
not accurately represent human breast cancers in
their appearance - Ethical pressure on scientists
- 3Rs
15Primary cultures derived from human material
- Pros
- established directly from tumours
- more representative models
- Biologically
- Clinically
- Cons
- difficult to establish
- slow doubling times
- contamination by fibroblasts/normal epithelial
cells - Ethical issues (HTA)
- Tissue access
16Breast Cancer Campaign
- Mission
- To beat breast cancer by funding innovative
world-class research to understand how breast
cancer develops, leading to improved diagnosis,
treatment, prevention and cure
17Background to Breast Cancer Campaign
- Breast Cancer Campaign is the only charity that
specialises in funding independent breast cancer
research throughout the UK - Supports high quality research (basic and
clinical) in universities, medical
schools/teaching hospitals and research
institutes in the UK and ROI
18- Since 1988 BCC have supported
- 183 grants
- 18.5 million
- Currently funds gt100 research projects throughout
the UK/ROI worth gt 13.5M - In Yorkshire, Campaign has supported
- 11 grants
- 1.25 million
19(No Transcript)
20- Breast Cancer Campaign
- http//www.truveo.com/breast-cancer-campaignE280
99s-research/id/3900128381
21Breast Cancer Campaign Gap Analysis
- One-day meeting convened in London on 2 November
2006 - 56 of the UKs most influential breast cancer
experts identified the key research gaps and
priorities for the greatest potential impact on
patients
22Format
- Before, during and after the meeting, groups in
seven key research areas participated in cycles
of presentation, literature review and discussion
23Groups
- Genetics
- Initiation
- Progression
- Therapies and targets
- Disease markers
- Prevention
- Psychosocial aspects
24Questions posed
- What do we know?
- What are the gaps?
- Problems
- Translational implications
- Recommendations
25- Summary papers were prepared by each group and
collated into a position paper highlighting the
research gaps, with recommendations for action
26(No Transcript)
27(No Transcript)
28(No Transcript)
29Mission Statement
- To provide, in partnership with BCC, highly
specialised breast cancer related biomaterials to
support cutting-edge translational research for
the benefit of the patient
30Why is the tissue bank so important?
- Access to standardised, well annotated human
breast tissue will help identify the causes of
breast cancer, develop new treatments, identify
genes associated with breast cancer and, most
importantly, accelerate research from the
laboratory to the clinic
31Questions?